PerioChip® (chlorhexidine gluconate) is a small, orange-brown, rectangular chip (rounded at one end) for insertion into periodontal pockets. Each PerioChip weighs approximately 7.4 mg and contains 2.5 mg of chlorhexidine gluconate in a biodegradable matrix of hydrolyzed gelatin (cross-linked with glutaraldehyde). PerioChip also contains glycerin and purified water.
Chlorhexidine gluconate is an antimicrobial agent.
PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing.
Published Studies Related to Periochip (Chlorhexidine)
Comparison of antibacterial effects of oral rinses chlorhexidine and herbal mouth
wash in patients admitted to intensive care unit. 
mouthwashes in intensive care unit patients... CONCLUSION: The herbal mouth wash has significant antibacterial effects against
Dose assessment of 2% chlorhexidine acetate for canine superficial pyoderma. [2011.10]
The dose of 2% chlorhexidine acetate (2CA; Nolvasan((R)) Surgical Scrub; Fort Dodge Animal Health, Fort Dodge, IA, USA) for canine superficial pyoderma was evaluated...
Clinical evaluation of chlorhexidine for the control of dental biofilm in children with special needs. [2011.09]
CONCLUSIONS: The topical administration of chlorhexidine associated to tooth brushing led to a reduction in dental biofilm and gingival bleeding in children with special needs. Administration in spray form proved easier and was preferred by parents/caregivers.
Early, single chlorhexidine application reduces ventilator-associated pneumonia in trauma patients. [2011.09]
BACKGROUND: Ventilator-associated pneumonia (VAP) is an important complication of mechanical ventilation and is particularly common in trauma, burn, and surgical patients. Interventions that kill bacteria in the oropharynx reduce the pool of viable organisms available for translocation to the lung and thereby lessen the likelihood of developing VAP. Repeated administration of chlorhexidine (CHX) to the mouth and oropharynx has been shown to reduce the incidence of VAP, but use of a single dose has not been studied. This randomized, controlled clinical trial tested an early (within 12 hours of intubation) application of CHX by swab versus control (no swab) on oral microbial flora and VAP... CONCLUSION: an early, single application of CHX to the oral cavity significantly reduces CPIS and thus VAP in trauma patients. Copyright (c) 2011 Elsevier Inc. All rights reserved.
A novel approach to the use of subgingival controlled-release chlorhexidine delivery in chronic periodontitis: a randomized clinical trial. [2011.08]
BACKGROUND: We aimed to analyze clinical, microbiologic, and serologic effects of chlorhexidine (CHX) chips used as a subgingival controlled-release delivery device before and immediately after scaling and root planing (SRP)... CONCLUSION: The use of CHX chips before and immediately after SRP improved CAL and reduced the subgingival microorganisms of the red complex in the treatment of chronic periodontitis.
Clinical Trials Related to Periochip (Chlorhexidine)
Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan [Recruiting]
The investigators hypothesize that application of 4% Chlorhexidine to the cord stump and
meticulous hand washing by primary health care providers of newborn infants will reduce the
incidence of Omphalitis and thereby Neonatal Mortality as compared to standardized dry cord
Efficacy Study Comparing 2% Chlorhexidine in 70% Isopropyl Alcohol Versus 2% Aqueous Chlorhexidine [Recruiting]
The purpose of this study is to compare the efficacy of two different antiseptic solutions
(2%chlorhexidine in 70% alcohol with 2% aqueous chlorhexidine)when used in a standardized
controlled manner in cleansing the skin of infants with birth weight less than 1500 grams
prior to a skin breaking procedure (venepuncture).
The investigators hypothesize that the use of limited amount of 2% aqueous chlorhexidine
solution will be as effective as the same amount of 2% chlorhexidine in 70% alcohol for skin
antisepsis and that limited exposure to 2% aqueous CHG may be associated with less adverse
Literature from adults has shown that both 2% chlorhexidine in 70% alcohol as well as 2%
aqueous chlorhexidine can provide effective skin antisepsis though alcohol containing
solution had more long lasting effect. It is also well known from many case reports that
alcohol containing products when used to clean abdominal skin for neonatal procedures can
cause severe skin damage in preterm infants. This has lead many neonatal units to adopt
aqueous chlorhexidine as the antiseptic agent of choice without robust evidence to support
its use or standardization of method of application. Both these solutions are widely used in
neonatal intensive care units across the globe including Canada.
By conducting this trial, the investigators want to evaluate the efficacy and safety of 2%
aqueous chlorhexidine as an antiseptic agent when used in a controlled manner [limited
amount for short duration].
The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip´┐Ż) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis [Recruiting]
Chlorhexidine Against Sodium Hypochlorite as Skin Antiseptics [Recruiting]
The physicians have few options for skin antisepsis. Alternatives for common use antiseptics
are costly or ineffective. In order to have more options, this study is needed. The
investigators want to know if there are differences between the use of 2% chlorhexidine
gluconate in 70% isopropyl alcohol or 10% sodium hypochlorite.
The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip«) in Therapy of Symptoms in Patients With Peri-implantitis [Recruiting]
The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate
chip (Periochip«) versus Placebo Chip in treatment of symptoms in patients with